- Conditions
- Small Cell Lung Cancer
- Interventions
- Carboplatin, Placebo, Trilaciclib, Etoposide
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Rogers, Arkansas • Whittier, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy, Obesity, Pharmacokinetics
- Interventions
- Valproic acid
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- TRK-250, Placebo
- Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 8 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- BMS-986278, Pirfenidone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
- Interventions
- IPI-504
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- DYNE-251, Placebo
- Drug
- Lead sponsor
- Dyne Therapeutics
- Industry
- Eligibility
- 4 Years to 16 Years · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy Volunteers
- Interventions
- [14C]-AZD4205, single 50 mg oral dose administrated on day 1
- Drug
- Lead sponsor
- Dizal Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
- Interventions
- Pharmacological Study, Romidepsin
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 11
- States / cities
- Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
- Conditions
- Asthma
- Interventions
- Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Anaemia
- Interventions
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Oklahoma City, Oklahoma • Houston, Texas
- Conditions
- Healthy
- Interventions
- Treatment with ARQ 197
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Healthy Participants
- Interventions
- midazolam, clofutriben once daily for 16 days, 2 single oral doses of prednisolone
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Type 1 Diabetes
- Interventions
- Insulin, Insulin LISPRO
- Drug
- Lead sponsor
- Hompesch, Marcus, M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Lung Non-Small Cell Carcinoma, Melanoma
- Interventions
- Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Participants
- Interventions
- AG-881, Lamotrigine
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Prostate Cancer
- Interventions
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
- Conditions
- Pain, Postoperative, Pain, Chest
- Interventions
- Ropivacaine 0.25%-NaCl 0.9% Injectable Solution, Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hepatic Impairment
- Interventions
- DZD9008
- Drug
- Lead sponsor
- Dizal Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Healthy Volunteers
- Interventions
- ATH-1105, Placebo
- Drug
- Lead sponsor
- LeonaBio
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pain
- Interventions
- Codeine
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cardiac Conditions
- Interventions
- Bupivacaine liposome
- Drug
- Lead sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida